AR040514A1 - Heterociclos diarilicos sustituidos, procedimiento para la preparacion de medicamentos y la utilizacion de los compuestos para tal fin - Google Patents

Heterociclos diarilicos sustituidos, procedimiento para la preparacion de medicamentos y la utilizacion de los compuestos para tal fin

Info

Publication number
AR040514A1
AR040514A1 AR20030102644A ARP030102644A AR040514A1 AR 040514 A1 AR040514 A1 AR 040514A1 AR 20030102644 A AR20030102644 A AR 20030102644A AR P030102644 A ARP030102644 A AR P030102644A AR 040514 A1 AR040514 A1 AR 040514A1
Authority
AR
Argentina
Prior art keywords
alkyl
aryl
independently
cycloalkyl
alkylene
Prior art date
Application number
AR20030102644A
Other languages
English (en)
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of AR040514A1 publication Critical patent/AR040514A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/91—Nitro radicals
    • C07D233/92—Nitro radicals attached in position 4 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/91—Nitro radicals
    • C07D233/92—Nitro radicals attached in position 4 or 5
    • C07D233/94—Nitro radicals attached in position 4 or 5 with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to other ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/04—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente se refiere a heterociclos diarílicos sustituidos, así como a su sales fisiológicamente tolerables y a sus derivados fisiológicamente funcionales. Compuestos de la fórmula (1), los compuestos son adecuados, por ejemplo, como agentes anoréxicos y para mantener un peso reducido en los mamíferos, ya que estos compuestos poseen efectos favorables sobre el metabolismo de las grasas. Reivindicación 1: Compuestos de la fórmula (1) en donde significan: R alquilo (C1-8), alquilen(C0-8)-arilo, cicloalquilo (C3-8), alcoxi(C1-4)-alquilo(C1-4), alquenilo (C2-8), alquinilo (C2-8); un anillo mono-, bi- o espirocíclico de 3-12 miembros, el cual puede contener uno o varios heteroátomos del grupo N, O y S, y el anillo de 3-12 miembros puede llevar otros sustituyentes tales como F, Cl, Br, NO2, CF3, OCF3, CN, alquilo (C1-6), arilo, CON(R11)(R12), N(R13(R14), OH, O-alquilo (C1-6), S-alquilo (C1-6), N(R15)CO-alquilo (C1-6) o COO-alquilo (C1-6); R11, R12, R13, R14, R15, independientemente entre sí, H, alquilo (C1-6), B es un enlace o un enlazador que se compone de uno o dos radicales del grupo (C(R19)(R20)), C(OR21)(R22), O, N(R23), S, SO, SO2, CO; i es 1, 2, 3; R19, R20, R21, R22, R23, independientemente entre sí, H, alquilo (C1-6), arilo; R1, R2, R3, R4, independientemente entre sí, H, F, Cl, Br, Y, OH, CF3, NO2, CN, OCF3, O-alquilo (C1-6), O-alcoxi(C1-4)-alquilo(C1-4), S-alquilo (C1-6), alquilo (C1-6), alquenilo (C2-6), cicloalquilo (C3-8), O-cicloalquilo (C3-8), cicloalquenilo (C3-8), O-cicloalquenilo (C3-8), alquinilo (C2-6), alquilen(C0-8)-arilo, O-alquilen(C0-8)-arilo, S-arilo, N(R24)(R25), SO2-CH3, COOH; COO-alquilo (C1-6), CON(R26)(R27), N(R28)CO(R29), N(R30)SO2(R31), CO(R32), R24, R25, R26, R27, R28, R30, independientemente entre sí, H, alquilo (C1-6); R29, R31, R32, independientemente entre sí, H, alquilo (C1-6), arilo; W es -(CH2)n-, -CH=CH-, -CH=N-, -N=CH-; n es 2, 3, 4 o 5; R5, R6, R7, R8, independientemente entre sí, H, F, Cl, Br, Y, OH, CF3, NO2, CN, OCF3, O-alquilo (C1-6), O-alcoxi(C1-4)-alquilo(C1-4), S-alquilo (C1-6), alquilo (C1-6), alquenilo (C2-6), cicloalquilo (C3-8), O-cicloalquilo (C3-8), cicloalquenilo (C3-8), O-cicloalquenilo (C3-8), alquinilo (C2-6), alquilen(C0-8)-arilo, O-alquilen(C0-8)-arilo, S-arilo, N(R33)(R34), SO2-CH3, COOH, COO-alquilo (C1-6), CON(R35)(R36), N(R37)CO(R38), N(R39)SO2(R40), CO(R41), un heterociclo de 5-7 miembros con 1-4 heteroátomos del grupo O, N y S; R33, R34, independientemente entre sí, H, alquilo (C1-6); o R33 y R34 forman, junto con el átomo de nitrógeno al que están unidos, un anillo de 5-6 miembros, pudiendo estar reemplazado un grupo CH2 por O o S en el caso del anillo de 6 miembros; R35, R36, R37, R39, independientemente entre sí, H, alquilo (C1-6); R38, R40, R41, independientemente entre sí, H, alquilo (C1-6), arilo; A es una cadena -(C(R42)(R43))m-, en la cual 0-2 miembros pueden estar reemplazados por un elemento del grupo O, S, N(R44), CO; SO2; m es 0, 1, 2, 3, 4, 5; R42, R43, R44, independientemente entre sí, H, alquilo (C1-6), arilo; R9, R10, independientemente entre sí, H, alquilo (C1-8), -(CH2)o-R45, alcoxi(C1-4)-alquilo(C1-4); ariloxi-alquilo (C1-4), alquenilo (C3-8), alquinilo (C3-8), CO-alquilo (C1-8), -CO-(CH2)0-R45, CO-alcoxi(C1-4)-alquilo(C1-4), CO-ariloxi-alquilo(C1-4), CO-alquenilo (C2-8), CO-alquinilo (C2-8); o R9 y R10 forman, junto con el átomo de nitrógeno al que están unidos, un anillo mono-, bi- o espirocíclico de 4-10 miembros, el cual aparte del átomo de nitrógeno puede contener 0 a 4 heteroátomos adicionales seleccionados del grupo oxígeno, nitrógeno y azufre, pudiendo estar sustituido adicionalmente el sistema anular heterocíclico con F, Cl, Br, CF3, NO2, CN, alquilo (C1-6), O-alquilo (C1-8), alcoxi(C1-4)-alquilo(C1-4), alquilen(C0-8)-arilo, oxo, CO(R46), CON(R47)(R48), hidroxi, COO(R49), N(R50)CO-alquilo(C1-6), N(R51)(R52) o SO2CH3; R46, R47, R48, R49, R50, R51, R52, independientemente son, H, alquilo (C1-6); o es 1, 2, 3, 4, 5, 6; R45 es OH, CH(arilo)2, un anillo mono- o bicíclico con 3-12 miembros, el cual puede contener uno o varios heteroátomos del grupo N, O y S, y el anillo de 3-12 miembros puede contener otros sustituyentes tales como F, Cl, Br, Y, OH, CF3, NO2, CN, OCF3, oxo, O-alquilo (C1-6), alcoxi(C1-4)-alquilo(C1-4), S-alquilo (C1-6), alquilo (C1-6) alquenilo (C2-6), cicloalquilo (C3-8), O-cicloalquilo (C3-8), cicloalquenilo (C3-8), O-ciclo-alquenilo (C3-8), alquinilo (C2-6), alquilen(C0-8)-arilo, O-alquilen(C0-8)-arilo, S-arilo, N(R51)(R52), SO2-CH3 y COOH; así como sus sales fisiológicamente tolerables.
AR20030102644A 2002-07-25 2003-07-23 Heterociclos diarilicos sustituidos, procedimiento para la preparacion de medicamentos y la utilizacion de los compuestos para tal fin AR040514A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10233817A DE10233817A1 (de) 2002-07-25 2002-07-25 Substituierte Diarylheterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
AR040514A1 true AR040514A1 (es) 2005-04-06

Family

ID=30128364

Family Applications (1)

Application Number Title Priority Date Filing Date
AR20030102644A AR040514A1 (es) 2002-07-25 2003-07-23 Heterociclos diarilicos sustituidos, procedimiento para la preparacion de medicamentos y la utilizacion de los compuestos para tal fin

Country Status (14)

Country Link
EP (1) EP1551810B1 (es)
JP (1) JP4568113B2 (es)
AR (1) AR040514A1 (es)
AT (1) ATE535513T1 (es)
AU (2) AU2003257465A1 (es)
BR (1) BR0312916A (es)
CA (1) CA2493924A1 (es)
DE (1) DE10233817A1 (es)
IL (1) IL166471A (es)
MX (1) MXPA05001048A (es)
MY (1) MY142551A (es)
PE (1) PE20040702A1 (es)
TW (1) TW200408627A (es)
WO (2) WO2004012648A2 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004003811A1 (de) * 2004-01-25 2005-08-11 Aventis Pharma Deutschland Gmbh Substituierte N-Cyclohexylimidazolinone, Verfahren ihrer Herstellung und ihre Verwendung als Arzneimittel
US7241787B2 (en) 2004-01-25 2007-07-10 Sanofi-Aventis Deutschland Gmbh Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
EP1727540A4 (en) * 2004-03-23 2009-07-22 Univ California ANTAGONISTS FOR MELANO-CONCENTRATION HORMONE RECEPTOR (MCH), AND METHODS OF USE
WO2006015279A1 (en) * 2004-07-28 2006-02-09 Neurogen Corporation Heterocyclic diamine compounds as ligands of the melanin concentrating hormone receptor useful for the treatment of obesity, diabetes, eating and sexual disorders
EP1634598A1 (en) * 2004-09-07 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Use of piperazine derivatives and analogues for the manufacture of a medicament for the prophylaxis and/or treatment of disorders of food ingestion
JP5250967B2 (ja) * 2005-11-30 2013-07-31 三菱化学株式会社 有機化合物、電荷輸送材料、電荷輸送材料用組成物および有機電界発光素子
WO2007063760A1 (ja) * 2005-11-30 2007-06-07 Mitsubishi Chemical Corporation 有機化合物、電荷輸送材料、電荷輸送材料用組成物および有機電界発光素子
JP5193878B2 (ja) 2005-12-21 2013-05-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｍｃｈ−１が媒介する疾患における使用のための新規な置換ピラジノン誘導体
JP2009526794A (ja) * 2006-02-15 2009-07-23 サノフィ−アベンティス 新規なアミノアルコール置換アリールチエノピリミジノン、それらの製造方法及び薬剤としてそれらの使用
BRPI0715160A2 (pt) 2006-08-08 2013-06-11 Sanofi Aventis imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
CN101541796B (zh) 2006-12-05 2012-11-07 詹森药业有限公司 用于mch-1介导的疾病的取代的二氮杂-螺-吡啶酮衍生物
EP2310372B1 (en) 2008-07-09 2012-05-23 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
DE102008049675A1 (de) 2008-09-30 2010-04-01 Markus Dr. Heinrich Verfahren zur Herstellung von 3-Aminobiphenylen
MX2011004258A (es) 2008-10-22 2011-06-01 Merck Sharp & Dohme Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos.
CN102271509A (zh) 2008-10-31 2011-12-07 默沙东公司 用于抗糖尿病药的新型环苯并咪唑衍生物
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
SG178880A1 (en) 2009-08-26 2012-04-27 Sanofi Sa Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
MY159058A (en) 2011-02-25 2016-12-15 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agent
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683701B1 (de) 2011-03-08 2014-12-24 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120057A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
RU2465895C1 (ru) * 2011-09-08 2012-11-10 Государственное образовательное учреждение высшего профессионального образования "Мордовский государственный университет им. Н.П. Огарева" Способ лечения депрессивного невроза
CA2880901A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US9840512B2 (en) 2013-02-22 2017-12-12 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
CN105473558B (zh) 2013-06-20 2019-04-19 拜耳作物科学股份公司 作为杀螨剂和杀昆虫剂的芳基硫化物衍生物和芳基硫氧化物衍生物
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2016100823A1 (en) 2014-12-19 2016-06-23 The Broad Institute, Inc. Dopamine d2 receptor ligands
US10633336B2 (en) 2014-12-19 2020-04-28 The Broad Institute, Inc. Dopamine D2 receptor ligands
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0002649A3 (en) * 1977-12-19 1979-07-11 Sandoz Ag 1-dimethyl-substituted alkyl-2- or 4-substituted phenylimidazoles, their production and their use as anti-obesity agents
DE4107857A1 (de) * 1991-03-12 1992-09-17 Thomae Gmbh Dr K Cyclische harnstoffderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
CA2211458A1 (en) * 1995-02-17 1996-08-22 Kenji Okonogi Azole compounds, their production and use
FR2764889B1 (fr) * 1997-06-20 2000-09-01 Sod Conseils Rech Applic Nouveaux derives du 2-(iminomethyl)amino-phenyle, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
WO1999048888A1 (en) * 1998-03-25 1999-09-30 Bristol-Myers Squibb Company Imidazolone anorectic agents: ii. phenyl derivatives
JP2002003370A (ja) * 1999-09-20 2002-01-09 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
US6569861B2 (en) * 2000-07-06 2003-05-27 Neurogen Corporation Melanin concentrating hormone receptor ligands
PL365183A1 (en) * 2000-07-31 2004-12-27 Smithkline Beecham P.L.C. Carboxamide compounds and their use as antagonists of a human 11cby receptor
GT200100147A (es) * 2000-07-31 2002-06-25 Derivados de imidazol
YU52403A (sh) * 2000-12-26 2006-03-03 Dr.Reddy's Research Foundation Heterociklična jedinjenja koja imaju antibakterijsko dejstvo, postupak za njihovo dobijanje i farmaceutske smeše koje ih sadrže
GB0200283D0 (en) * 2002-01-08 2002-02-20 Smithkline Beecham Plc Compounds

Also Published As

Publication number Publication date
MY142551A (en) 2010-12-15
WO2004012648A2 (de) 2004-02-12
AU2003251001B9 (en) 2010-03-04
AU2003251001B2 (en) 2010-01-21
ATE535513T1 (de) 2011-12-15
CA2493924A1 (en) 2004-02-05
EP1551810A1 (de) 2005-07-13
AU2003257465A1 (en) 2004-02-23
JP2006501202A (ja) 2006-01-12
DE10233817A1 (de) 2004-02-12
IL166471A (en) 2009-09-01
BR0312916A (pt) 2005-06-14
TW200408627A (en) 2004-06-01
WO2004011438A1 (de) 2004-02-05
AU2003251001A1 (en) 2004-02-16
IL166471A0 (en) 2006-01-15
PE20040702A1 (es) 2004-11-30
EP1551810B1 (de) 2011-11-30
MXPA05001048A (es) 2005-04-08
JP4568113B2 (ja) 2010-10-27

Similar Documents

Publication Publication Date Title
AR040514A1 (es) Heterociclos diarilicos sustituidos, procedimiento para la preparacion de medicamentos y la utilizacion de los compuestos para tal fin
AR061114A1 (es) Arilimidazolonas y ariltriazolonas sustituidas asi como su uso
AR047454A1 (es) Oxadiazoles sustituidos y composiciones farmaceuticas que los contienen.
AR059458A1 (es) Arildihidroisoquinolinonas sustituidas con azaciclilo, procedimiento para su preparacion y su uso como medicamentos
AR043477A1 (es) Compuestos biciclicos aromaticos sustituidos con amino-alquilo y composiciones farmaceuticas que los contienen
AR067444A1 (es) Derivados de pirazinona, procesos de obtencion y composiciones farmaceuticas
AR050604A1 (es) Aminas policiclicas sustituidas con arilo, procedimientos para su preparacion y su uso como medicamentos
AR059522A1 (es) Arildihidroisoquinolinas sustituidas con aminoalcoholes, procedimiento para su preparacion y su uso como medicamentos
AR076486A1 (es) Inhibidores de fosfoinositida 3 kinasa y composiciones farmaceuticas que los contienen.
AR059521A1 (es) Ariltienopirimidinas sustituidas con azaciclilo, procedimiento para su preparacion y su uso como medicamentos
AR043648A1 (es) Derivados de bencenosulfonamida
AR067327A1 (es) Derivados de piperidina / piperazina
AR067757A1 (es) Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales.
AR087273A1 (es) 3-(fluorovinil)pirazoles y su uso
AR082768A1 (es) Derivados de indolizina, su procedimiento de preparacion y composiciones farmaceuticas que los contienen
AR079483A1 (es) Inhibidores heterociclicos de la esfingosina quinasas, composiciones farmaceuticas que los contienen, procedimiento para prepararlos y uso de los mismos en enfermedades hiperproliferativas y/o inmunologicas.
AR082112A1 (es) Derivados de imidazopiridina, su procedimiento de preparacion y su aplicacion en terapeutica
AR075402A1 (es) Derivados heterociclicos oxigenados y/o nitrogenados de tetrahidronaftaleno, medicamentos que los contienen y uso de los mismos en el tratamiento de trastornos metabolicos, tales como obesidad,entre otros.
AR083635A1 (es) Compuestos y derivados sustituidos de isoxazolina que contienen azolin para combatir plagas animales
AR037736A1 (es) Derivados de pirimidina como moduladores o inhibidores de la actividad del factor de crecimiento insulinico tipo 1 (igf-1r)
AR039112A1 (es) Inhibidores de quinasas
AR085987A1 (es) Compuestos tri- y tetraciclicos pirazol[3,4-b]piridina como agentes antineoplasicos
AR076435A1 (es) Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
AR087182A1 (es) DERIVADOS DE INDOL SUSTITUIDOS COMO MODULADORES DE g SECRETASA
CO5640152A2 (es) Composiciones farmaceuticas para inhibidores de la proteasa del virus de la hepatitis c

Legal Events

Date Code Title Description
FB Suspension of granting procedure